Fundraising Fox
/Companies
Sign in

Mirecule

Gaithersburg, US · Founded 2018 · Delaware corporation · 8 known investors

Find your way into Mirecule

Sign up to see every warm intro you have to Mirecule

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Mirecule team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

miRecule is a biotechnology company developing therapeutics, with programs focused on oncology. It applies RNA-based drug development approaches within the biotech industry.

BiotechHealthtech

Founders & leadership

Mirecule was founded in 2018 by Anthony D. Saleh.

ADAnthony D. Saleh
Anthony D. SalehCo-founder and CEOBefore co-founding miRecule in 2018, Saleh served as Entrepreneur in Residence at BioHealth Innovation and as President of MIMETAS US and Director of Product R&D at MIMETAS BV. His research career includes postdoctoral fellowships at the National Cancer Institute and NIDCD, followed by work as a scientist in the Tumor Biology Section of the NIH Intramural Research Program.
DLDave Lemus
Dave LemusCOO/CFOHe has held C-level executive roles in US and European pharmaceutical and biotech companies, with experience in R&D organizations and specialty pharma, and has served as a non-executive board director for multiple public and private companies.

Investors · 8

Boutique Venture Partnerslisted by Boutique Venture PartnersPalo Alto

How we know: Boutique Venture Partners's portfolio page · Not right? Tell us

Brown and White Ventureslisted by Brown and White VenturesFairport

How we know: Brown and White Ventures's portfolio page · Not right? Tell us

Pathway Bioventureslisted by Pathway BioventuresChicago
Tachyon Ventureslisted by Tachyon VenturesLos Angeles
University System of Maryland Momentum Fundlisted by University System of Maryland Momentum FundBaltimore · $150K – $500K

How we know: University System of Maryland Momentum Fund's portfolio page · Not right? Tell us

AlexandriareportedPasadena

How we know: funding news · Not right? Tell us

Also in the syndicate · 1

SOLVE FSHD

Reported raises · per SEC filings

Form D private placements

$1.5M disclosed across 1 of 3 rounds · 2019–2022

▶$1.5MraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony SalehExecutive Officer
Offering amount
$2.3M
Amount sold
$1.5M
Minimum investment
$100K
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

UniqureuniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
IecureiECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
EmoleculeseMolecules operates a digital chemical search platform and procurement service connecting researchers to over 83 million available chemical compounds from a global supplier network. The company serves drug discovery researchers and biopharmaceutical organizations seeking to reduce timelines and improve efficiencies in early-stage compound acquisition and management.

Companies working in the same space as Mirecule.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$739.2K
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$305K
National Institutes of Health (NIH)National Institutes of HealthPhase I2017$410.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD) - BioSpacebiospace.com · Oct 2022miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophyfinance.yahoo.com · May 2021

Frequently asked questions

What does Mirecule do?
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology. It applies RNA-based drug development approaches within the biotech industry.
Who founded Mirecule?
Mirecule was founded by Anthony D. Saleh in 2018.
Who are Mirecule's investors?
Mirecule's investors include Alumni Ventures, Boutique Venture Partners, Brown and White Ventures, Pathway Bioventures, Tachyon Ventures, University System of Maryland Momentum Fund, Alexandria.
How much funding has Mirecule raised?
Mirecule has disclosed $1.5M raised across 1 of its 3 known rounds.
Where is Mirecule headquartered?
Mirecule is headquartered in Gaithersburg, US.